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ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH
NON-MYELOABLATIVE CONDITIONING IN PATIENTS WITH ACUTE MY-
ELOGENOUS LEUKEMIA ELIGIBLE FOR CONVENTIONAL ALLOGRAFT-
ING: RESULTS OF A PROSPECTIVE, MULTICENTER STUDY
Ruiz-Arguelles, G.J.1,2, Gomez-Almaguer, D.3, Gomez-Rangel, D.1,
Vela-Ojeda, J.4, Cantu-Rodriguez, O.G.3, Jaime-Perez, J.C.3, Her-
rera-Garza, J.L.3, Gonzalez-Llano, O.3 1. Centro de Hematologia y
Medicina Interna de Puebla, Puebla, PUE, Mexico; 2. Laboratorios
Clinicos de Puebla, Puebla, PUE, Mexico;3. Hospital Universitario de
Monterrey, Monterrey, NL, Mexico;4. Centro Medico La Raza, Mexico
City, DF, Mexico.
Using a lymphoablative, non-myeloablative stem cell trasplanta-
tion (NST) program, 25 allografts were prospectively given to 24
patients with acute myelogenous leukemia (AML) eligible for con-
ventional allografting; two individuals had secondary forms of
AML. The median age of the patients was 35 years, with a range of
12 to 56. All patients engrafted; median time to achieve an absolute
neutrophil count 0.5 x 109/L was 12 days (range 0-26), whereas
the median time to a platelet count20 x 109/L was 13 days (range
0-26). Patients developed chimerism 15 to 100 (median 30) days
after the allograft. The follow-up periods range between 33 and
2664 days (median 450). The median post-transplant overall sur-
vival has not been reached and is above 89 months, whereas the
89-month both, overall and progression-free survival is 56%, the
683-day survival being 66%. In 14 grafts (56%) acute GVHD
ensued; in 12 cases grades I-II and in 2 cases grade IV which was
fatal in both. In 9/20 grafts (45%) limited chronic GVHD devel-
oped. In 22 cases (88%), the procedure could be completed fully on
an outpatient basis. The 100-day and the transplant-related mor-
tality were both 8%. The median cost of the allografts until day
100 was 20 000 USD. NST appears to be an effective additional
therapeutic option for patients with AML in remission and a
matched donor available.
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A SINGLE CENTRE, RANDOMISED TRIAL ON HARVEST CELL YIELD AND
MARROW ENGRAFTMENT USING HAEMOPOIETIC GROWTH-FACTOR
PRIMED BONE MARROW
Lu, K.H., Liang, R.H.S., Kwong, Y.L, Lie, A.K.W., Leung, Y.H. The
University of Hong Kong, Hong Kong.
The use of haemopoietic growth factors (HGFs) in the BMT
setting is most often administered to recipients during the post-
BMT period to enhance neutrophil recovery. However, there is
little or no effect on platelet recovery when HGFs are administered
in this fashion. The aim of this study is to compare HGFs primed
and unprimed marrow in terms of: the haemopoietic stem and
progenitor cell yields; the neutrophil and platelet engraftment in
allogeneic BMT; and the incidence and severity of GVHD as well
as other complications in allogeneic BMT. Methods: Thirteen
patient-donor pairs were randomized to the G-CSF group, eleven
pairs to the GM-CSF group and thirteen pairs to the control
group. The donors randomized to group I received 10g/kg per
day G-CSF subcutaneously for four days before the bone marrow
was harvested. The donors randomized to group II received
10g/kg per day GM-CSF subcutaneous injection for four days
before the bone marrow was harvested. The donors randomized to
the control arm did not receive any growth factors before the bone
marrow was harvested. Results: The median total nucleated cell
count was slightly higher in primed BM graft. For the G-CSF
primed BM , 5.77 x 108/kg, and for the GM-CSF primed BM
3.18 x 108/kg compared to 2.23 x 108/kg for the unprimed BM
graft (Kruskal Wallis test, P  0.001). The central tendency was
signiﬁcantly different (Kruskal Wallis Test, P  0.003) between
the three groups for the CFU-GM/kg measure. The median was
17.44 x 104/kg in the G-CSF group, 6.14 x 104/kg in the GM-CSF
group and 10.12 x 104/kg in the control group. The mean time to
obtain an ANC value above 1.0 x 109/L was statistically signiﬁcant
among the three groups (ANOVA, P  0.046); the mean duration
for group I, II and III was 23 days, 30 days and 29 days, respec-
tively. We found that G-CSF primed BM had signiﬁcantly faster
engraftment of ANC 1.0 x 109/L, compared to GM-CSF primed
BM and unprimed BM. Besides, the units of RBC used post BMT
were signiﬁcantly less than the other two groups. G-CSF priming
increased total nucleated cells and proliferation of CFU-GM in the
marrow graft.
In summary, we found that BM priming with both G-CSF and
GM-CSF increases the number of total nucleated cells in marrow.
BM priming with G-CSF also increased the number of CFU-GM
and promoted early engraftment post BMT. Post BMT complica-
tions and death rate were relatively lower.
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OPTIMIZING RESULTS OF NON-MYELOABLATIVE ALLOGENEIC TRANS-
PLANTATION (NMAT): IDENTIFICATION OF PATIENTS AT HIGH RISK OF
TREATMENT FAILURE BASED UPON PRE-TRANSPLANT VARIABLES
Verma, A., Gordon, L., Singhal, S., Tallman, M., Williams, S., Win-
ter, J., Mehta, J. Northwestern University, Chicago.
47 consecutive patients (27-68 y; median 51) with hematologic
malignancies were studied to develop a scoring system to identify
those at high (HR) and low (LR) risk of transplant-related mor-
tality (TRM) and relapse (REL) based on pretransplant factors.
The conditioning regimen was 100 mg/m2 melphalan on day-1
(50 mg/kg cyclophosphamide on day-2 if no prior autograft),
cyclosporine (HLA-matched sibling; n  32) or tacrolimus (1-
locus mismatched sibling; n  3, or unrelated; n  12), and
mycophenolate mofetil. The 2-y cumulative incidences of TRM
and REL were 20% and 50%, with 2-y actuarial disease-free (DFS)
and overall (OS) survival probabilties of 30% and 40% respec-
tively. TRM was higher with creatinine 1.5 mg/dL (2 points),
HLA mismatch (2 points), poor performance status (0-3 points),
and age 60 (1 point). The 11 patients with a total score of2 points
(HR-TRM) had signiﬁcantly higher TRM than the 36 with a score
of 0-2 (LR-TRM) (64% vs 7%; P  0.0005). REL was higher with
non-chemosensitive disease (2 points), platelets 100 x 109/L (1
point), and prior autograft (1 point). The 15 patients with a total
score of 2 points (HR-REL) had signiﬁcantly higher REL than
the 21 with a score of 0-2 (LR-REL) (83% vs 21%; P  0.003)
after eliminating HR-TRM patients from the analysis. Overall, the
outcome of the 21 LR patients was signiﬁcantly better than the 26
HR patients (11 HR-TRM, 15 HR-REL) in terms of OS (92% vs
19% at 1.5 y; P  0.0001) and DFS (70% vs 6% at 1.5 y; P 
0.0001). The model will be tested in the next 50 patients treated
similarly. If it is validated, the regimen intensity will be lowered for
HR-TRM patients to reduce TRM. From the remaining patients,
HR-REL patients will be identiﬁed and their regimen intensiﬁed
to decrease REL. For both the groups with modiﬁed conditioning,
GVHD prophylaxis will be changed (e.g. omission of mycopheno-
late) to augment graft-vs-tumor. Patients who are LR for both
TRM and REL will continue to receive the current therapy in view
of their excellent outcome. We conclude that the outcome of LR
patients undergoing NMAT is excellent. In such patients, this
mode of transplantation should be considered standard therapy
rather than investigational. Conﬁrmation of our observations may
justify using NMAT as a safer alternative procedure for patients
who fulﬁll the LR criteria speciﬁed here but who would normally
undergo conventional allogeneic transplantation. Modiﬁed treat-
ment may improve the outcome of HR patients.
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